NCT04976270View on ClinicalTrials.gov

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions
Healthy
Interventions
DRUG

GLPG3667

GLPG3667 capsules

DRUG

Placebo

Matching placebo capsules

Trial Locations (1)

9000

Drug Research Unit Ghent, Ghent

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY